TATE Share Price Performance
UK£5.62
0.07 (1.26%)
16.1% overvalued intrinsic discount
UK£4.84
Fair Value
Price UK£5.62
AnalystConsensusTarget UK£4.84
AnalystLowTarget UK£3.75
AnalystHighTarget UK£6.67
Fair ValueUK£4.84
Share Pricen/a
Tate & Lyle plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 59 Fair Values set on narratives written by author
TATE Community Narratives
AN
Fair Value
·Fair Value UK£4.84 16.1% overvalued intrinsic discount
TATE: Revenue Guidance Revisions Will Drive Near-Term Re-Rating Opportunity
3users have liked this narrative
0users have commented on this narrative
36users have followed this narrative
AN
Fair Value
·Fair Value UK£3.75 49.7% overvalued intrinsic discount
Regulatory And Integration Hurdles Will Constrain Upside But Spur Revaluation
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value
·Fair Value UK£6.67 15.9% undervalued intrinsic discount
Rising Health Trends And Urbanization Will Expand Specialty Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory And Integration Hurdles Will Constrain Upside But Spur Revaluation
Tate & Lyle is pushing deeper into specialty ingredients after buying CP Kelco, but bringing the businesses together may take longer than investors expect. At the same time, tighter food rules, higher compliance costs, and shifting consumer tastes could squeeze demand and profits even as the company chases healthier food trends.Read more
AN
UK£3.75
49.7% overvalued intrinsic discount
Fair Value
Revenue
2.68% p.a.
Profit Margin
7.75%
Future PE
12.23x
Price in 2029
UK£4.64
Rising Health Trends And Urbanization Will Expand Specialty Markets
Key Takeaways Synergy gains, innovation-driven specialty revenue growth, and superior solution-selling could significantly boost margins, operating leverage, and earnings beyond current expectations. Expansion in emerging markets and rising global demand for healthier food ingredients position Tate & Lyle for long-term revenue gains and increased pricing power.Read more
AN
UK£6.67
15.9% undervalued intrinsic discount
Fair Value
Revenue
4.34% p.a.
Profit Margin
10.6%
Future PE
15.27x
Price in 2029
UK£8.23
TATE: Revenue Guidance Revisions Will Drive Near-Term Re-Rating Opportunity
Key Takeaways Expansion through CP Kelco enhances specialty solutions, driving revenue growth and improving profitability via anticipated cost synergies and EBITDA margin uplift. Strong cash flow and disciplined financial management fuel share buybacks, increasing EPS, while innovation drives new revenue streams and strengthens market position.Read more
AN
UK£4.84
16.1% overvalued intrinsic discount
Fair Value
Revenue
2.73% p.a.
Profit Margin
9.08%
Future PE
13.54x
Price in 2029
UK£5.97
Trending Discussion
Recently Updated Narratives
AN
TATE: Future Earnings Profile Will Reflect Cautious Margins Under Takeover Overhang
Fair Value: UK£3.75 49.7% overvalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TATE: Higher Future P/E Assumptions Will Support Bullish Case For Upside
Fair Value: UK£6.67 15.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TATE: Reset Price Expectations Will Support Future Upside If Margins Hold
Fair Value: UK£4.84 16.1% overvalued intrinsic discount
36 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Tate & Lyle plc Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Nov 05, 2026
- 0.22
- 45.81%
- 4.84%
- 77.5%
About TATE
- Founded
- 1903
- Employees
- 4840
- CEO
- WebsiteView website
Tate & Lyle plc, together with its subsidiaries, engages in the provision of ingredients and solutions to the food, beverages, and other industries in North America, Asia, Middle East, Africa, Latin America, and Europe. Its portfolio includes sweeteners, fibres, stabilisers and functional systems, hydrocolloids, and starches, proteins, and functional flours. The company’s products are used in beverages, dairy, soups, sauces and dressings, bakery and snacks, confectionery, household, clinical nutrition, industrial, meat and seafood, and personal care applications. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.
